USFDA issues EIR to Medak facility of Suven Life Sciences

Suven Life Sciences Limited received Establishment Inspection Report (EIR) from US drug regulator for its Pashamylaram, Medak facility.

The USFDA conducted the inspection in February 2018. The regulator certified that the manufacturing facility complies with the standards of Current Good Manufacturing Processes (cGMP). The company has filed 19 Drug Master Files and 5 ANDAs from this facility.

Suven Life Sciences is a bio-pharma company based in Hyderabad based. The company manufactures and supplies APIs (bulk drugs), intermediates and formulations under cGMP. It is a leading manufacturer under Contract Research and Manufacturing Services (CRAMS) and Drug Discovery and Development program.

Meanwhile at 14:55 hours, the stock of Suven Life Sciences was quoting Rs. 190.65 per share, up by 5.19 per cent on Monday.